NASDAQ:AKRX - Akorn Stock Price, Forecast & News

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn, Inc. (NASDAQ:AKRX) issued its quarterly earnings data on Thursday, October, 31st. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.06. The firm earned $176.24 million during the quarter, compared to analysts' expectations of $176.15 million. Akorn had a negative net margin of 53.62% and a negative return on equity of 19.95%. The business's revenue was up 6.4% on a year-over-year basis. During the same period last year, the company earned ($0.06) earnings per share. View Akorn's Earnings History.

4 brokers have issued 1-year price objectives for Akorn's stock. Their forecasts range from $4.00 to $11.00. On average, they anticipate Akorn's share price to reach $7.00 in the next year. This suggests a possible upside of 86.7% from the stock's current price. View Analyst Price Targets for Akorn.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.

Media coverage about AKRX stock has trended extremely negative this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akorn earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Akorn.

Akorn saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 7,650,000 shares, a decrease of 17.6% from the September 30th total of 9,280,000 shares. Based on an average daily trading volume, of 1,860,000 shares, the days-to-cover ratio is presently 4.1 days. Approximately 8.1% of the shares of the company are short sold. View Akorn's Current Options Chain.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (2.66%), State Street Corp (2.60%), Canyon Capital Advisors LLC (2.38%), Mackay Shields LLC (0.57%), Gabelli Funds LLC (0.35%) and Gamco Investors INC. ET AL (0.29%). Company insiders that own Akorn stock include Alan D Weinstein, John N Kapoor, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.

AKRX stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, State Street Corp, Assenagon Asset Management S.A., Barclays PLC, SG Americas Securities LLC, Chicago Equity Partners LLC and Gabelli Funds LLC. View Insider Buying and Selling for Akorn.

AKRX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Mackay Shields LLC, Canyon Capital Advisors LLC, Tibra Equities Europe Ltd, State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Gamco Investors INC. ET AL and California Public Employees Retirement System. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKRX stock can currently be purchased for approximately $3.75.

Akorn has a market capitalization of $473.05 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

The official website for Akorn is http://www.akorn.com/.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]